Singapore Biopharma Manufacturer Raises $200 Million Series A

Published: May 27, 2021
By Alex Keown
Singapore-based Esco Lifesciences closed a 
$200 million oversubscribed Series A financing and crossover round that will enable the company that provides life sciences tools and services to expand its toehold in China and the United States. 
Esco is a manufacturer of laboratory and biopharma equipment and IVF medical devices. The company has four different divisions, Scientific, Medical, Healthcare, and Aster, which offers “mission-critical equipment and advanced solutions” to laboratories, clinics, and bio-pharma production sites in over 100 countries. 
The company employs more than 1,300 people across the globe. It has offices in more than 100 companies, including eight manufacturing and R&D hubs in the US, Europe, the UK, China, and Singapore. The financing round is the largest private fundraising round by an Asia-based life sciences tools company, Esco said in its announcement. 

Related Keywords

China , Boston , Massachusetts , United States , Denmark , United Kingdom , Singapore , Shan Fu , Zhejiang , Kasim Kutay , Esco Lifesciences , Amit Kakar , China Investment Corporation , Novo Holdings Asia , Novo Holdings , Vivo Capital , Iesco Board , Greater China , Resume , Careers , Ingapore Biopharma Manufacturer Raises 200 Million Series A , Iospace , Advice , சீனா , போஸ்டன் , மாசசூசெட்ஸ் , ஒன்றுபட்டது மாநிலங்களில் , டென்மார்க் , ஒன்றுபட்டது கிஂக்டம் , சிங்கப்பூர் , ஷான் ஃபூ , ஜெஜியாங் , எஸ்கோ ஆயுள் அறிவியல் , அமித் கக்கர் , சீனா முதலீடு நிறுவனம் , நோவோ ஹோல்டிங்ஸ் , விவோ மூலதனம் , அதிகமானது சீனா , தற்குறிப்பு ,